Semaglutide, lipid-lowering drugs, and NAFLD - Author's reply

Lancet Diabetes Endocrinol. 2017 May;5(5):330. doi: 10.1016/S2213-8587(17)30110-9.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Glucagon-Like Peptides*
  • Humans
  • Lipids
  • Non-alcoholic Fatty Liver Disease*

Substances

  • Lipids
  • semaglutide
  • Glucagon-Like Peptides